OP0181- What are the best drugs to treat D2T RA? In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action @RheumNow #EULAR2024

OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis #EULAR24 @RheumNow

I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events. Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early! #EULAR2024 OP0114 @karolinskainst @RheumNow https://t.co/Q8dIHiIYQk

• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1
• https://twitter.com/drdavidliew/status/1801182711882875027/photo/1

#EULARBest OP0156- validation & prevalence of D2T RA Data from @BrighamResearch BRASS In this cohort, the #EULAR definition of D2TRA correctly identified a subset of RA pts who have not achieved low disease activity despite multiple b/ts DMARD treatments #EULAR2024 @RheumNow

OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024

Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively? VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed. I’ll admit, I’m still not game! #EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov

• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1
• https://twitter.com/drdavidliew/status/1801179511561785657/photo/1

How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis? Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed. #EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC

• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1
• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1
• https://twitter.com/drdavidliew/status/1801176356224680405/photo/1

OP0131 on occurrence & predictors of #DMARD treatment failure in #RA 8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs @RheumNow #EULAR2024

🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA 📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA 💊MTX after start of advanced therapy protective of D2T RA @RheumNow #EULAR2024